Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $120
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $160 to $120.
Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $160 to $120.